Effects of saxagliptin on <i>β</i> ‐cell stimulation and insulin secretion in patients with type 2 diabetes

Abstract

DPP-4 inhibition with saxagliptin improves pancreatic β-cell function in postprandial and fasting states, and decreases postprandial glucagon concentration. Given the magnitude of enhancement of the insulin response in the fasting state, further study into the effect of DPP-4 inhibition on the β-cell is warranted.